NJ Bio and Charles River Forge Strategic Alliance to Advance ADC Development and Manufacturing
Wednesday, November 06, 2024
NJ Bio and Charles River Laboratories have announced a strategic partnership to offer comprehensive services for the development and manufacturing of antibody-drug conjugates (ADCs).
The complex nature of ADC development and manufacturing requires specialized expertise and seamless integration of various processes. The alliance between Charles River and NJ Bio offers clients a streamlined approach, accelerating time-to-market and enhancing the overall success of ADC programs.
Charles River, renowned for its leadership in antibody development and preclinical evaluation of ADCs, will provide support from proof-of-concept to clinical candidate stages.
Their team of experts in antibody, oncology, immunology, and safety assessment will drive translational success and expedite the path to clinical trials.
NJ Bio, a leading contract research organization specializing in chemistry and bioconjugation services, will contribute its expertise in the synthesis and GMP manufacturing of payloads, linkers, linker-payloads, ADCs, and other related compounds.
The company's strong track record in early-phase discovery, proof-of-concept, and clinical-grade manufacturing will further strengthen the alliance's capabilities.
By combining their strengths, Charles River and NJ Bio aim to advance the field of ADC development and deliver innovative therapies to patients.
Source: businesswire.com
